NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results